Latest News

  • Proscia, Nucleai Partner to Link Digital Pathology, AI-Predictive Biomarker Platforms

    Diagnostics World | Proscia and Nucleai are partnering to integrate Nucleai’s predictive biomarker solutions into Proscia’s Concentriq software platform and make them available as part of Proscia’s AI-enabled pathology portfolio to better inform patient care.

    Jul 9, 2024
  • New AI System Detects Rare Forms of Epilepsy Better Than Traditional Models

    Diagnostics World | Over 3.4 million people in the US and 65 million people worldwide are affected by epilepsy. To ensure that patients are getting the treatment they need, early detection is critical. Researchers at the University of Southern California have developed an AI system called NeuroGNN that can identify epilepsy by analyzing brain interactions with greater accuracy and efficiency.

    Jul 1, 2024
  • Follow the Money: Foresite Therapeutics’ New Fund Invests in Precision Therapeutics, Targeting Autoimmune, Inflammatory Diseases, More

    Diagnostics World | Foresite Capital launches fund for three main areas: precision therapeutics, life science infrastructure, and healthcare delivery; Santa Ana Bio employs proteomic, transcriptomic, and genomic approaches to precisely characterize disease-specific subpopulations and identify targets only on disease-causing cell types leaving healthy cells unaffected; more.

    Jun 27, 2024
  • PacBio’s Free HiFi Long-Read Variant Frequency Database, PathAI Releases New AI Products, Thermo Fisher Unveils New Pipetting System, More

    Diagnostics World | PacBio, in collaboration with the international Consortium for Long-Read Sequencing (CoLoRS), announced the launch of the first publicly available and free HiFi long-read variant frequency database with global representation; PathAI unveiled two novel AI products, PathExplore Immuno-Oncology Profiling (IOP) and IHC Explore1; , Thermo Fisher Scientific has introduced One Lambda HLA PRO, an automated, modular pipetting system that offers versatility by accommodating different workflows on a single instrument, allowing laboratories to automate multiple human leukocyte antigen (HLA) and antibody testing technologies cost-effectively; more.

    Jun 26, 2024
  • GRAIL Begins Independent Trading on Nasdaq

    Diagnostics World | GRAIL, previously an Illumina company, began regular trading on Nasdaq today under the ticker symbol "GRAL." Illumina continues to trade on Nasdaq under the ticker symbol "ILMN."

    Jun 25, 2024
  • Wearable Device Identifies Biomarker for Malignant Melanoma

    Diagnostics World | Researchers at the Karolinska Institute in Stockholm, Sweden, have developed a new device for detecting malignant melanoma. Melanoma affects about one million people every year across the world, and over the past two decades, cases of melanoma have significantly increased due to higher rates of exposure to ultraviolet radiation and climate change.

    Jun 21, 2024
  • AI-Powered Platform Could Reveal True Personality of Tumors

    Diagnostics World | Researchers in Israel who pioneered the discipline of “mechanomics” are now using the concept to fill the chasm between the expanding volume of ‘omics data and its translation into real-world clinical scenarios. Their aim is to help physicians predict the aggressiveness of cancer and a tumor’s potential resistance to treatment and, ultimately, improve patient outcomes.

    Jun 18, 2024